Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
86.45
-0.82 (-0.94%)
Jul 25, 2025, 4:00 PM - Market closed
Rhythm Pharmaceuticals Revenue
Rhythm Pharmaceuticals had revenue of $32.70M in the quarter ending March 31, 2025, with 25.94% growth. This brings the company's revenue in the last twelve months to $136.86M, up 48.88% year-over-year. In the year 2024, Rhythm Pharmaceuticals had annual revenue of $130.13M with 68.06% growth.
Revenue (ttm)
$136.86M
Revenue Growth
+48.88%
P/S Ratio
39.36
Revenue / Employee
$483,615
Employees
283
Market Cap
5.66B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
RYTM News
- 3 days ago - Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - GlobeNewsWire
- 12 days ago - Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 - GlobeNewsWire
- 15 days ago - Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market - Seeking Alpha
- 15 days ago - Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewsWire
- 15 days ago - Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 16 days ago - Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity - GlobeNewsWire
- 17 days ago - Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity - GlobeNewsWire
- 25 days ago - Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent Prospects - Seeking Alpha